HeartBeam has developed a 3D-vector electrocardiogram (VECG) platform that synthesizes a 12-lead ECG using a portable, credit card-sized device. This technology enables patients to capture heart signals from three distinct directions, allowing physicians to detect non-life-threatening arrhythmias that traditional at-home monitors cannot identify.
Funding
$23.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional 12-lead electrocardiograms (ECGs) require trained healthcare professionals and are impractical for frequent at-home use, hindering timely detection of non-life-threatening arrhythmias. Existing at-home monitors often lack the fidelity to capture comprehensive heart signals, leading to missed diagnoses and delayed care.
Solution
HeartBeam offers a compact, patient-friendly ECG system designed to synthesize a 12-lead ECG from anywhere. The system comprises a credit card-sized device, the HeartBeam AIMIGo, and a patient mobile app that guides users through the recording process. The device captures heart signals from three distinct directions, enabling physicians to detect a broader range of arrhythmias compared to conventional at-home monitors. Recordings are transmitted to the HeartBeam cloud, where on-call physicians can review the data and facilitate timely follow-up with patients.
Target Audience
The primary target audience includes individual patients seeking convenient at-home heart monitoring, as well as healthcare providers looking to improve arrhythmia detection and patient care.
Features
- Credit card-sized HeartBeam AIMIGo device for on-the-go ECG recordings
- Patient mobile app with step-by-step guidance for accurate data capture
- High-fidelity ECG approach capturing heart signals from three distinct directions
- Wireless data transmission to the HeartBeam cloud for physician review
- Capability to synthesize a 12-lead ECG (Note: 12-lead synthesis software not cleared by the FDA and not available for sale in the United States)